The significant role and far-reaching efficacy of capmatinib in the treatment of non-small cell lung cancer

Capmatinib (Capmatinib), as a cutting-edge oral small molecule drug, has demonstrated significant efficacy in patients with non-small cell lung cancer (NSCLC). It works primarily by inhibiting the activity of mesenchymal-to-epithelial transition (MET) factor tyrosine kinase receptors. Its unique mechanism makes capmatinib an important treatment option for selected NSCLC patients.

The reason why capmatinib was approved for marketing was mainly based onthe excellent performance of the GEOMETRY mono-1 trial. The trial not only demonstrated capmatinib's initial overall response rate and duration of response, but also further validated its durability of response and clinical benefit with data from an additional 63 patients and up to 22 months of follow-up.

The main effect of capmatinib is that it can effectively inhibit the excessive activity ofc-Met. c-Met is a receptor tyrosine kinase encoded by the Met proto-oncogene, and its mutations are closely related to the proliferation of various cancers, NSCLC being one of them. The efficacy of capmatinib was strongly confirmed in a study involving 160 patients with metastatic NSCLC harboring MET exon 14 skipping mutations. These patients received 400 mg of capmatinib orally twice daily until disease progression or unacceptable toxicity.

The primary endpoints for assessing the efficacy of capmatinib include overall response rate (ORR) and duration of response (DOR) as determined by a blinded independent review committee (BIRC). Among patients receiving second-line or later-line treatment, the ORR was as high as 51.6%. Among newly treated patients, the ORR reached an astonishing 68%, and the DOR was extended to 16.6 months. For previously treated patients, the ORR was also 44% and the DOR was 9.7 months.

Overall, capmatinib, as an innovative drug, has demonstrated significant effects and far-reaching efficacy in the treatment of non-small cell lung cancer, providing patients with new treatment options and hope.